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Author's repiy
Sir—T he effect of chronic potent 
combination antiretroviral therapy 
(also described as HAART) on the 
natural history of specific AIDS- 
related opportunistic infections such 
as CMV retinitis is largely 
undocumented. We reported five 
unusual cases of CMV retinitis who 
had in common clinical presentation 
soon after HAART regimens were 
initiated, and at a time when 
previously very low absolute CD4 
lymphocyte counts had risen (in 
response to HAART) to values of 200 
cells/jLtL or greater. These values are 
much higher than previously reported 
in patients with this AIDS-related 
complication. We also noted in a 
prospective clinical trial a temporal 
trend toward higher absolute CD4 
counts occurring in patients with 
CMV retinitis diagnosed after the 
widespread availability of the potent 
HIV pro tea se inhibitors indinavir and 
ritonavir than in those diagnosed 
before. These objective observations 
were the basis of our report.
We, in our report3 and your 
correspondents speculate about what 
these findings mean. Uthayakumar 
and colleagues and Stein provide 
additional observations to support the 
hypothesis that HAART does allow 
reconstitution of protective CMV- 
specific immunity. Certainly* our 
observations are consistent with this 
hypothesis^ given the presence of 
vitritis in two of the five cases and the 
subsequent prolonged time without 
retinitis progression in all five. In fact, 
since publication of our report, 
ophthalmological examinations 
indicate that after 8-17 months of 
treatment, none of these five patients 
have yet to show progression of 
retinitis, We speculated3 like Stein3 
that these cases could have had 
subclinical CMV retinal infection that
was unmasked by a HAART-induced 
immune inflammatory response. At 
scientific meetings, others have also 
reported CMV retinitis developing in 
the first 2 months after the institution 
of HAART, but not in subsequent 
months.1-3 One would expect retinitis 
to occur with increasing rather than 
decreasing frequency after HA ART- 
induced absolute CD4 count rises if 
these increases did not represent 
improved functional immunity. On the 
other hand, Mitchell and colleagues5 
hypothesis that functional CMV 
immunity takes several months to be 
restored and that of Carr and Cooper 
that improved CMV immunity may be 
anatomically restricted and not 
penetrate into the eye are equally 
plausible.
However, to put these speculations 
in perspective, we note that neither we 
nor any of your correspondents have 
any direct evidence proving that 
HAART does or does not allow 
reconstitution of clinically meaningful 
CMV-specific protective immunity in 
vivo. S earching for such direct 
evidence should now be a high priority 
objective of clinical research.
In response to specific questions 
raised3 first, none of the patients 
described were receiving anti-CMV 
monoclonal antibody at the time that 
CMV retinitis was diagnosed. Second, 
routine ophthalmological monitoring 
began only after retinitis was 
;nosed. Third , the nadir CD4 
counts reported, ranging from 14 to 82 
cells/fiL, were obtained 1-17 weeks 
before HAART was initiated. And last, 
of the patients enrolled in ACTG 
protocol 266 between July, 1995, and 
August, 1996, four of 16 whose 
baseline absolute CD4 count was 50 
cells/|iL or greater had initiated 
ritonavir, indinavir, or saquinavir 
therapy within 8 weeks before 
enrolment and three of these 16 had 
initiated protease inhibitor therapy 
greater than 8 weeks before enrolment.
Mark A Jacobson
University of California San Francisco AIDS Program, 
San Francisco General Hospital, San Francisco,
CA 94110, USA
1 Michelet C, Arvieux C, Aubert Vj et al. 
Viral ocular involvement after initiation of 
antiprotease inhibitor therapy. 4th 
Conference on Retroviruses and 
Opportunistic Infections, W ashington DC 
1997 (abstr 315),
2 Gilquin J3 Piketty C, Thomas V, et al.
Acute CMV infection in AIDS patients 
receiving combination therapy including 
protease inhibitors. 4th Conference on 
Retroviruses and Opportunistic Infections, 
Washington DC 1997 (abstr 354).
3 Cameron B, Heath-Chiozzi M, Kravcik S, 
et al. Prolongation of life and prevention of 
AIDS in advanced HIV immunodeficiency 
with ritonavir. 3rd Conference on 
Retroviruses and Opportunistic Infections, 
Washington D C 1996 (abstr LBa).
Cold exposure and winter 
mortality in Europe
Sir—In the Euro winter Group’s (May 
103 p 1341)1 report on cold-related 
mortality in warm and cold regions of 
Europe, the increase in mortality with 
given fall of temperature in regions with 
warmer winters are associated with 
cooler homes3 less appropriate clothing, 
and decreased activity outdoors. 
However, as Amy Sperber and Simon 
Weitzman state in their commentary,2 
the causal and temporal relation 
between observed risk factors (eg3 
living-room temperature) and cold- 
related mortality remains controversial 
and many questions remain to be 
elucidated. The mean percentage 
increase in mortality with each 1°C fall 
from 18°C was the lowest in Finland 
and highest in Athens; however, the 
striking differences in mortality with 
given fall of temperature between 
regions with virtually identical mean 
winter temperature (London 7*6°C and 
north Italy 7-7°C; 1*37 and 0-51% 
mortality increase, respectively), 
indicate a more complex relation.
A single recording of living-room 
temperature during the interview is not 
representative for the average indoor 
temperature during winter and does not 
reflect circadian fluctuations in ambient 
temperature. Were additional cold- 
protective measures during the night 
(eg, use of an electric blanket) or 
differences in insulation of housing 
units investigated? The observed 
differences in indoor heating 
conditions, clothing, and outdoor 
physical activity during cold exposure 
between residents of cold and warm 
regions can partly account for the lower 
mortality in the former group. On the 
basis of differences in shivering and 
sweating in the cold, more adequate 
acclimatisation to cold exposure 
probably contributed to the lower 
mortality in colder regions.
The Eurowinter Group analysed 
several risk factors for cold-related 
mortality, and emphasised the 
importance of adequate modulation of 
clothing and environmental conditions. 
Other relevant factors that affect the 
ability to withstand cold stress and its 
complications include adequate intake of 
(warm) food and drinks, subcutaneous 
fat content, nutritional state, 
muscularity, extremes of age, physical 
fitness, cold awareness3 underlying 
medical diseases, use of drugs and 
alcohol, as well as wind velocity and air 
humidity.3,1 Furthermore, both 
individual and clinical experience with 
cold-related disorders can greatly affect 
survival outcome.
Efficient thermoregulatory behaviour 
is pivotal to survival in cold regions and 
to reduction of cold-related morbidity
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and mortality, particularly in 
patients with impaired autonomic 
thermoregulation.3*4 Depending on 
environmental conditions and other risk 
factors, failure of autonomic or 
behavioural thermoregulation can cause 
fluctuations of core temperature or overt 
hypothermia or hyperthermia with 
potentially lethal consequences.3'5 Even 
small decreases in core temperature 
can induce striking changes in 
cardiovascular, (neuro) physiological, 
and immunological responses;4,5 hence, 
core temperature should be taken into 
account in the analysis of cold-related 
disorders. Since core temperature and 
underlying medical disorders were not 
evaluated in the Eurowinter study, the 
relation between these variables 
and cold-related mortality remains 
uncertain.
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Sir—The Eurowinter Group’s report 
on cold exposure and winter mortality*1 
presents important fin dings , but the 
investigators draw inferences beyond 
the limits of the data and study design. 
First, in an ecological study of this sort 
individual risk factors are not related to 
individual outcomes; thus, causality 
cannot be proved. To demonstrate 
associations in an ecological study, it is 
essential that the populations used 
should be as similar as possible with 
respect to time and population 
characteristics. We assume that quota 
sampling was used to obtain the survey 
sample in this study, although the 
methods are not made explicit. This 
method is likely to have resulted in an 
unrepresentative population. For 
example, population groups unavailable 
at the time of survey, (eg, shift workers, 
and those without permanent 
residence) may not have been included. 
Such potential sources of bias have not 
been assessed in this study.
Second, the study is limited in its
approach to the explanation of potential 
protective and risk factors for cold- 
related deaths. For example, it would 
have been helpful to take into account 
race, family history, diet, and other 
cultural factors. Genetic variation in 
both risk factors for cardiovascular 
disease and adaptation to cold may 
affect mortality outcomes. In addition, 
although the wearing of hats may be an 
important protective measure, it is 
likely that hat wearing is determined by 
other cultural factors as well as outdoor 
temperatures.
This is an important research study 
that has highlighted significant 
associations between mortality and cold 
exposure, but the data and study design 
do not support conclusions about 
causality. The logical next step should 
be prospective studies of the relation 
between cold exposure and mortality. 
Such studies could also examine the 
effects of climate on morbidity, which 
may be equally important.
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Sir—T he report by the Eurowinter 
Group1 presents fascinating evidence 
tha t the association between low 
temperature and mortality is not 
constant across Europe. The finding 
that the slope of the association is 
steeper in countries with warmer 
winters may have implications for 
interpretation of studies of the 
association between daily mortality and 
air pollution. Although most of these 
studies found a positive association, 
even after statistically controlling for 
daily mean temperature., there are some 
inconsistencies with respect to the 
strength of the assocation. We suggest 
that part of this inconsistency between 
studies may be attributable to residual 
confounding by temperature. The 
argument is as follows: (1) daily 
temperature is inversely correlated with 
daily concentrations of sulphur dioxide 
and particulates; (2) temperature is 
inversely related to mortality; and (3) 
crude (bivariate) association between 
pollution and mortality is substantially 
attenuated by adjustment for 
temperature, suggesting a confounding 
role of temperature, It is plausible that 
the use of a single daily value of 
temperature may not be sufficient to 
remove entirely all the effect of 
temperature. Additionally, any residual 
confounding by temperature would be 
stronger in southern countries where
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the slope of the association between 
temperature and mortality is steeper. 
As a consequence, the effects of 
pollution would seem stronger in 
countries with warmer winters.
This is the case in the APHEA 
project which analysed daily mortality 
and air pollution in several European 
countries, In this project^ the effect of 
air pollution was apparent in centres in 
western and south Europe, but was 
weak or absent in central Europe.2 
Explanation for this inconsistency is not 
clear. We speculate that the difference 
in the effects of pollution between the 
regions can be caused by differences in 
winter temperatures, since average 
winter temperatures in central Europe 
were substantially lower than in the 
west or south (table). Unfortunately, 
the effects of daily concentration of 
pollutants on deaths were not presented 
in identical units in the APHEA 
reports, and this speculation cannot be 
directly examined in published data. 
However, this is a testable suggestion 
that may also be relevant for studies 
outside Europe.
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Authors’ reply
Sir—M arius Mackenzie asks whether 
the large differences in winter mortality 
that we reported between different 
regions of western Europe were 
attributable to the concomitant 
differences that we reported in cold 
exposure.
Our study did deal with the main 
alternative possibilities that he suggests. 
Variations in age structure were avoided
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